GNLX:NASDAQ
Genelux Corp
US$ 2.52
arrow_downward
-0.98%(-0.025) Siku 1
13 Okt, 16:00:01 GMT -4 · USD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya GNLX...
Fungua
US$ 2.53
Juu
US$ 2.54
Chini
US$ 2.48
Mtaji wa soko
113.79M
Wastani wa kiasi cha mauzo
elfu 249.28
Kiasi cha mauzo ya hisa
elfu 151.82
Juu kwa wiki 52
US$ 8.54
Chini kwa wiki 52
US$ 2.29
EPS
-US$ 0.87
Beta
0.59
Hisa za wawekezaji
45.24M
Idadi ya wafanyakazi
26
Fungua
US$ 2.53
Juu
US$ 2.54
Chini
US$ 2.48
Mtaji wa soko
113.79M
Wastani wa kiasi cha mauzo
elfu 249.28
Kiasi cha mauzo ya hisa
elfu 151.82
Juu kwa wiki 52
US$ 8.54
Chini kwa wiki 52
US$ 2.29
EPS
-US$ 0.87
Beta
0.59
Hisa za wawekezaji
45.24M
Idadi ya wafanyakazi
26
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
https://www.dars.gov.et/
·
mwezi 1 uliopita
GNLX Q2 2026 Earnings: Wider-than-Expected Loss Reflects Continued Clinical Investment - Consensus Miss Rate
Wasifu
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Kuhusu Genelux Corp
Afisa Mkuu Mtendaji (CEO)-
Wafanyakazi26
Lilianzishwa2001
Makao makuuWestlake Village, California, Marekani
Sekta-
Tovutigenelux.com